Catalent Expands Its Technology Offerings in Biologics, Acquires Redwood Bioscience Inc. and the SMARTag™ Technology Platform
02 Oktober 2014 - 3:00PM
Business Wire
Acquires Full Ownership Based on Compelling
Technical Data and Strong Customer Response
Catalent Pharma Solutions, the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products, today announced that it has
acquired the remaining stake in Redwood Bioscience Inc., and the
SMARTag Antibody-Drug Conjugate (ADC) technology platform. In
Catalent’s first acquisition since its IPO in July, the company
continues to execute its strategy to build a differentiated
technology offering and strengthen its position in the fast growing
biologics market.
The acquisition follows the successful achievement of in vivo
and in vitro proof of concept milestones, recent compelling in vivo
toxicology data, and strong customer interest in the SMARTag
technology. Catalent will acquire the remaining outstanding shares
of Redwood. Redwood’s team in Emeryville, CA, will become part of
Catalent’s network under the leadership of Redwood President, CSO
and Founder, David Rabuka, who will continue to advance the
development of the SMARTag technology as part of Catalent’s growing
Biologics business.
Catalent announced in April 2013 that it had acquired an
exclusive license to market the SMARTag technology and has
subsequently collaborated with Redwood for the ongoing development
and marketing of the platform.
“This acquisition brings to Catalent a highly differentiated
technology in the SMARTag platform, as well as a high caliber and
innovative scientific team,” commented John Chiminski, President
and CEO, Catalent Pharma Solutions. “It is aligned with our
strategic focus on innovation and technology, and further
demonstrates Catalent’s ability to strengthen our position in key
growth markets through internal and external investments.”
Barry Littlejohns, Catalent’s President of Advanced Delivery
Technologies added, “In vivo toxicology studies have demonstrated
that an ADC generated using the SMARTag platform has a better
toxicity profile than a conventional ADC, and with efficacy
studies, point to an improved therapeutic index. This acquisition
builds on our recent investment in a state-of-the-art
Biomanufacturing facility and underpins our strategy of investing
in innovative technologies and differentiated solutions in the
biologics space.”
The novel, site-specific SMARTag technology enables the
generation of homogenous bioconjugates, engineered to improve
performance and ease of manufacturing. Combined with
Catalent’s proprietary GPEx® cell line expression system, its new
state-of-the-art biomanufacturing Center of Excellence in Madison,
Wisconsin, and broad range of analytical and fill-finish services,
this latest investment marks a further expansion of Catalent’s
capabilities to help customers develop more and better biologics
treatments.
About Catalent
Catalent Pharma Solutions is the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products. With over 80 years serving
the industry, Catalent has proven expertise in bringing more
customer products to market faster, enhancing product performance
and ensuring reliable clinical and commercial product supply.
Catalent employs approximately 8,000 people, including over 1,000
scientists, at nearly 30 facilities across 5 continents, and in
fiscal 2014 generated more than $1.8 billion in annual revenue.
Catalent is headquartered in Somerset, N.J. For more information,
visit www.catalent.com
More products. Better treatments. Reliably supplied.™
Forward-Looking Statements
This press release contains both historical and forward-looking
statements. All statements other than statements of historical fact
are, or may be deemed to be, forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements generally can be identified by the
use of statements that include phrases such as “believe,” “expect,”
“anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”,
“likely”, “may”, “will”, “would” or other words or phrases with
similar meanings. Similarly, statements that describe our
objectives, plans or goals are, or may be, forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could
vary materially from Catalent, Inc.’s expectations and projections.
Some of the factors that could cause actual results to differ
include, but are not limited to, the following: general industry
conditions and competition; product or other liability risk
inherent in the design, development, manufacture and marketing of
our offerings; inability to enhance our existing or introduce new
technology or services in a timely manner; economic conditions,
such as interest rate and currency exchange rate fluctuations;
technological advances and patents attained by competitors; and our
substantial debt and debt service requirements that restrict our
operating and financial flexibility and impose significant interest
and financial costs. For a more detailed discussion of these and
other factors, see the information under the caption “Risk Factors”
in its Form 10-K release for the fiscal year ended June 30, 2014
filed with the Securities and Exchange Commission. All
forward-looking statements speak only as of the date of this
release or as of the date they are made, and Catalent, Inc. does
not undertake to update any forward-looking statements as a result
of new information or future events or developments unless required
by law.
Catalent Pharma SolutionsMedia:Chris Halling, +44 (0)7580
041073chris.halling@catalent.comorRichard Kerns, +44 (0) 161 728
5880richard@nepr.eu
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024